Post-stem cell transplant maintenance in FLT3mut acute myeloid leukemia - A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib

Post-stem cell transplant maintenance in FLT3^mut acute myeloid leukemia - A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib

EJHaem. 2024 Apr 8;5(2):423-427. doi: 10.1002/jha2.885. eCollection 2024 Apr.

¹ University of Southern California Keck School of Medicine Los Angeles California USA.
² Internal Medicine Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases University of Southern California Norris Comprehensive Cancer Center Los Angeles California USA.
³ Department of Pathology University of Southern California Keck School of Medicine Los Angeles California USA.

No abstract available

Keywords: AML; FMS‐like tyrosine kinase 3 (FLT3) inhibitor; HSCT; gilteritinib; maintenance; midostaurin.